Last edition
News about "India Pharmaceutical Market (IPM)"
Alkem Reports Record FY26 EBITDA as Revenue Grows 13.5%; Q4 Profit Before Tax Rises 40.7 Percent
Alkem Laboratories posted its highest-ever EBITDA in FY26, driven by strong growth in domestic and international businesses, improved operating leverage, and disciplined cost management. The company also reported robust fourth-quarter performance, with revenue rising 14.6 percent and PBT before exceptional items increasing 40.7 percent YoY.
India Pharmaceutical Market (IPM) | 29/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy